Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026)

Organon (OGN) posted quarterly Non-Current Deferred Tax Liability of $56.0 million for Q1 2026, down 18.84% year-over-year from $69.0 million in Q1 2025, and down 1.75% on a QoQ basis from $57.0 million in Q4 2025.

Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends

Organon (OGN) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $56.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Non-Current Deferred Tax Liability fell 18.84% year-over-year to $56.0 million; the TTM figure through Mar 2026 stood at $56.0 million (down 18.84% YoY), while the FY2025 annual figure was $57.0 million, down 65.24% from the prior year.
  • Non-Current Deferred Tax Liability came in at $56.0 million for Q1 2026 at Organon, down from $57.0 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $164.0 million in Q4 2024, with the low at $2.0 million in Q1 2022.
  • Average Non-Current Deferred Tax Liability over 5 years is $51.5 million, with a median of $47.0 million recorded in 2023.
  • Across the five-year window, Non-Current Deferred Tax Liability slumped 98.4% in 2022 and surged 1400.0% in 2023, its largest moves.
  • Year by year, Non-Current Deferred Tax Liability stood at $19.0 million in 2022, then jumped by 147.37% to $47.0 million in 2023, then soared by 248.94% to $164.0 million in 2024, then slumped by 65.24% to $57.0 million in 2025, then dropped by 1.75% to $56.0 million in 2026.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $56.0 million, $57.0 million, and $62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Organon 3.53 Bn 2.41 Bn 783.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 56.00 Mn
Mar 31, 2026 56.00 Mn
Dec 31, 2025 57.00 Mn
Dec 31, 2025 57.00 Mn
Sep 30, 2025 62.00 Mn
Sep 30, 2025 62.00 Mn
Jun 30, 2025 69.00 Mn
Jun 30, 2025 69.00 Mn
Mar 31, 2025 69.00 Mn
Mar 31, 2025 69.00 Mn
Dec 31, 2024 164.00 Mn
Dec 31, 2024 164.00 Mn
Sep 30, 2024 56.00 Mn
Sep 30, 2024 56.00 Mn
Jun 30, 2024 60.00 Mn
Jun 30, 2024 60.00 Mn
Mar 31, 2024 44.00 Mn
Mar 31, 2024 44.00 Mn
Dec 31, 2023 47.00 Mn
Dec 31, 2023 47.00 Mn